Silvio Inderbitzin

Silvio Inderbitzin currently works at Mavena International AG, as Chief Executive Officer, Hänseler Holding AG, as Chairman, Hthc High Tech Home Care AG, as Chairman from 2018, Vital Solutions Swiss AG, as Chairman from 2015, Ulrich Jüstrich Holding AG, as Director from 2015, Helvecura Cooperative Society, as Director, Hänseler AG, as Director from 2016, Krebsforschung Schweiz, as Director, Nexilis AG, as Director from 2015, Swiss Cancer Foundation, as Director, Aurealis Oy, as Director, Cellestia Biotech AG, as Director from 2022, Just Finance AG, as Director, Aurealis Therapeutics AG, as Director, Curatis Holding AG, as Non-Executive Director from 2022, Aurealis Pharma AG, as Director from 2016, Helvecura Genossenschaft, as Director, Artidis AG, as Director from 2016, and Kinarus AG, as Director.
Dr. Inderbitzin also formerly worked at Spexis Ltd., as Independent Director, Spirig Pharma AG, as Chief Executive Director & Director from 2012 to 2013, MEDUDEM AG, as Director, Kinarus Therapeutics Holding AG, as Director, Strekin AG, as Member-Supervisory Board, and Swiss Pharmaceutical Co. Ltd., as Head-Quality Assurance.
Dr. Inderbitzin received his Masters Business Admin degree in 2002 from the University of St. Gallen and doctorate degree in 1995 from the University of Zurich.